Frailty in uremia: A survey on the effects of CKD 3-5 on physical functioning and -activity, quality of life and nutritional state

Recruiting

• Conditions: Chronic kidney disease / Kidney faillure; 10029149

• Registration Number: NL-OMON54748
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2024-04-15

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 131

Inclusion Criteria

Patients:
• The population consists of patients attending the predialysis out-patient
clinic, in which stage 3-5
CKD is diagnosed.
• Age> or equal to 18 years.
• Ability to provide written informed consent.,

Controls:
• Age> or equal to 18 years.
• Ability to provide written informed consent.
• If known with hypertension: well controlled bloodpressure (systolic <140mmHg
and/or diastolic <90mmHg) with the use of hypertensive medication

Exclusion Criteria

Patients:
• Inability to provide informed consent
• Active symptomatic coronary artery disease or cardiac failure NYHA class III
or IV, whitin 3 months before inclusion
• Active malignancies, with a life expectancy of less then 1 year
• Active infections, whitin 3 months before inclusion
CKD after transplantation
• For bioimpedance measurements: presence of ICD or pacemaker. There are no
restrictions for other measurements in these patients.

Controls:
• Inability to provide informed consent
• Hypertension (with or without the use of hypertensive medication) with a
blood pressure higher than 160 mmHg systolic and/or diastolic larger than 100
mmHg during the screening.
• Diabetes Mellitus
• Self-reported cardiovascular disease / chronic kidney disease

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of the study is to assess the longitudinal effects of<br /><br>differences and changes in renal function at CKD stage 3-5 on physical<br /><br>functioning. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary objectives of the study are to assess the longitudinal effects of<br /><br>differences and changes in renal function at CKD stage 3-5 on physical<br /><br>activity, nutritional status, cardiovascular function, quality of life, symptom<br /><br>burden, illness perception, anxiety and depression.</p><br>